A hearing on 15 November in the US of the House of Representatives’ Energy and Commerce Health Subcommittee1 was an opportunity for the heads of the Food and Drug Administration's drug centers to boast about the progress the agency has made in implementing FDASIA, the FDA Safety and Innovation Act. It also gave lawmakers a forum at which to crow about one of the few accomplishments they've made in the past year in the current rancorous Washington environment.
However, also at the meeting. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, warned that the...
